IL235338A0 - N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide - Google Patents
N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamideInfo
- Publication number
- IL235338A0 IL235338A0 IL235338A IL23533814A IL235338A0 IL 235338 A0 IL235338 A0 IL 235338A0 IL 235338 A IL235338 A IL 235338A IL 23533814 A IL23533814 A IL 23533814A IL 235338 A0 IL235338 A0 IL 235338A0
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- pentahydroxyhexyl
- dihydroquinoline
- carboxamide
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644054P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/039911 WO2013169746A2 (en) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL235338A0 true IL235338A0 (en) | 2014-12-31 |
Family
ID=49551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235338A IL235338A0 (en) | 2012-05-08 | 2014-10-26 | N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8809537B2 (enExample) |
| EP (1) | EP2697201A4 (enExample) |
| KR (1) | KR20150022816A (enExample) |
| CN (1) | CN104395291B (enExample) |
| AR (1) | AR090975A1 (enExample) |
| AU (1) | AU2013259779B2 (enExample) |
| BR (1) | BR112014028121A2 (enExample) |
| CA (1) | CA2873258A1 (enExample) |
| EA (1) | EA201492029A1 (enExample) |
| HK (1) | HK1207080A1 (enExample) |
| IL (1) | IL235338A0 (enExample) |
| IN (1) | IN2014MN02485A (enExample) |
| MX (1) | MX2014013664A (enExample) |
| NZ (1) | NZ630549A (enExample) |
| SG (1) | SG11201407447XA (enExample) |
| TW (1) | TW201350467A (enExample) |
| UY (1) | UY34791A (enExample) |
| WO (1) | WO2013169746A2 (enExample) |
| ZA (1) | ZA201408825B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| AU2014236232A1 (en) | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2159804A (en) * | 1937-11-23 | 1939-05-23 | Du Pont | N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US6043006A (en) * | 1997-09-04 | 2000-03-28 | Fuji Photo Film Co., Ltd. | 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| YU86001A (sh) | 1999-06-07 | 2004-07-15 | Altana Pharma Ag. | Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| PT1937642E (pt) | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| NZ573846A (en) * | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| AU2008242703B2 (en) | 2007-04-19 | 2011-08-18 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2010028015A2 (en) | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| DK2467372T3 (en) | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| KR20130036217A (ko) | 2010-03-03 | 2013-04-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 관절염의 치료 |
| BR112012022187A2 (pt) | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| JP2012047974A (ja) * | 2010-08-26 | 2012-03-08 | Toshiba Corp | 映像表示装置及び映像表示方法 |
| JP5676769B2 (ja) * | 2010-10-14 | 2015-02-25 | イムナール アクティエボラーグ | Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド |
| MX2013006464A (es) | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
| EP2736335A4 (en) | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
| WO2013016686A1 (en) | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2013
- 2013-05-02 TW TW102115767A patent/TW201350467A/zh unknown
- 2013-05-07 CN CN201380029448.XA patent/CN104395291B/zh not_active Expired - Fee Related
- 2013-05-07 WO PCT/US2013/039911 patent/WO2013169746A2/en not_active Ceased
- 2013-05-07 EP EP13750833.9A patent/EP2697201A4/en not_active Withdrawn
- 2013-05-07 NZ NZ630549A patent/NZ630549A/en not_active IP Right Cessation
- 2013-05-07 AR ARP130101569A patent/AR090975A1/es unknown
- 2013-05-07 UY UY0001034791A patent/UY34791A/es not_active Application Discontinuation
- 2013-05-07 BR BR112014028121A patent/BR112014028121A2/pt not_active IP Right Cessation
- 2013-05-07 HK HK15107804.4A patent/HK1207080A1/xx unknown
- 2013-05-07 SG SG11201407447XA patent/SG11201407447XA/en unknown
- 2013-05-07 EA EA201492029A patent/EA201492029A1/ru unknown
- 2013-05-07 IN IN2485MUN2014 patent/IN2014MN02485A/en unknown
- 2013-05-07 KR KR20147034461A patent/KR20150022816A/ko not_active Withdrawn
- 2013-05-07 AU AU2013259779A patent/AU2013259779B2/en not_active Expired - Fee Related
- 2013-05-07 US US13/888,709 patent/US8809537B2/en not_active Expired - Fee Related
- 2013-05-07 CA CA2873258A patent/CA2873258A1/en not_active Abandoned
- 2013-05-07 MX MX2014013664A patent/MX2014013664A/es unknown
-
2014
- 2014-10-26 IL IL235338A patent/IL235338A0/en unknown
- 2014-12-02 ZA ZA2014/08825A patent/ZA201408825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014028121A2 (pt) | 2017-06-27 |
| NZ630549A (en) | 2016-01-29 |
| US8809537B2 (en) | 2014-08-19 |
| HK1207080A1 (en) | 2016-01-22 |
| MX2014013664A (es) | 2015-04-17 |
| EA201492029A1 (ru) | 2015-06-30 |
| SG11201407447XA (en) | 2015-02-27 |
| UY34791A (es) | 2013-11-29 |
| CN104395291B (zh) | 2017-07-28 |
| EP2697201A4 (en) | 2014-11-26 |
| WO2013169746A2 (en) | 2013-11-14 |
| KR20150022816A (ko) | 2015-03-04 |
| WO2013169746A3 (en) | 2013-12-05 |
| ZA201408825B (en) | 2016-07-27 |
| IN2014MN02485A (enExample) | 2015-07-17 |
| AR090975A1 (es) | 2014-12-17 |
| CA2873258A1 (en) | 2013-11-14 |
| EP2697201A2 (en) | 2014-02-19 |
| AU2013259779A1 (en) | 2014-12-18 |
| CN104395291A (zh) | 2015-03-04 |
| AU2013259779B2 (en) | 2017-06-08 |
| TW201350467A (zh) | 2013-12-16 |
| US20130345256A1 (en) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201306229B (en) | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines | |
| ZA201408825B (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide | |
| GB201214120D0 (en) | Yota 070812 | |
| PL2851075T3 (pl) | Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu | |
| GB201200518D0 (en) | Wizz-through 2 (cielings) | |
| GB201210424D0 (en) | Poop - pole N?2 | |
| GB201200323D0 (en) | Easihang 45?/90? | |
| GB201220196D0 (en) | Magno-rebel 1 | |
| GB201214054D0 (en) | Pakaging 0 | |
| GB201208532D0 (en) | SockScreen 2 | |
| GB201206581D0 (en) | CityJaw 1830 | |
| GB201200834D0 (en) | Vinsole 3 | |
| GB201219458D0 (en) | Concept 70 | |
| GB201214012D0 (en) | Concept 35 | |
| GB201214046D0 (en) | Concept 4 | |
| GB201214092D0 (en) | Concept 3 | |
| GB201214026D0 (en) | Concept 40 | |
| GB201214025D0 (en) | Concept 39 | |
| GB201214031D0 (en) | Concept 15 | |
| GB201214001D0 (en) | Concept 32 | |
| GB201214006D0 (en) | Concept 33 | |
| GB201214008D0 (en) | Concept 11 | |
| GB201214051D0 (en) | Concept 12 | |
| GB201214050D0 (en) | Concept 44 | |
| GB201214049D0 (en) | Concept 43 |